Low- but not high-dose FK506 treatment confers atheroprotection due to alternative macrophage activation and unaffected cholesterol levels

Lili Bai, Karen Gabriels, Erwin Wijnands, Mat Rousch, Mat J.A.P. Daemen, J. W. Cohen Tervaert, Erik A. L. Biessen, Sylvia Heeneman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)143-150
JournalThrombosis and Haemostasis
Issue number1
Publication statusPublished - Jul 2010


  • Atherosclerosis
  • FK506
  • immunosuppression
  • NEAT

Cite this